Prostate Cancer Archives

177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

PHS290: a novel scoring algorithm provides a promising approach to screening for prostate cancer in diverse populations

A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

Key updates from EAU 2021

VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!

Top picks from ASCO 2021

VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

Darolutamide gets the OK in Europe for nmCRPC

Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the…

features: Prostate Cancer